Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Notes Payables: 2012-2014

Historic Notes Payables for Ligand Pharmaceuticals (LGND) over the last 3 years, with Dec 2014 value amounting to $196.2 million.

  • Ligand Pharmaceuticals' Notes Payables rose 3341.97% to $198.6 million in Q1 2015 from the same period last year, while for Mar 2015 it was $198.6 million, marking a year-over-year increase of 3341.97%. This contributed to the annual value of $196.2 million for FY2014, which is 2054.37% up from last year.
  • According to the latest figures from FY2014, Ligand Pharmaceuticals' Notes Payables is $196.2 million, which was up 2,054.37% from $9.1 million recorded in FY2013.
  • Over the past 5 years, Ligand Pharmaceuticals' Notes Payables peaked at $196.2 million during FY2014, and registered a low of $9.1 million during FY2013.
  • Its 3-year average for Notes Payables is $73.4 million, with a median of $14.8 million in 2012.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Notes Payables slumped by 38.60% in 2013, and later skyrocketed by 2,054.37% in 2014.
  • Over the past 3 years, Ligand Pharmaceuticals' Notes Payables (Yearly) stood at $14.8 million in 2012, then tumbled by 38.60% to $9.1 million in 2013, then skyrocketed by 2,054.37% to $196.2 million in 2014.